Sarclisa® (isatuximab) Phase 3 IKEMA trial meets primary endpoint early in patients with relapsed multiple myeloma

NEXT STORY
RedHill Biopharma erhält FDA-Genehmigung für eine klinische Studie in den USA zur Untersuchung von Opaganib für die Behandlung von COVID-19-Patienten
PREV STORY
Adamis Pharmaceuticals Provides Update on SYMJEPI Products and Announces Distribution and Commercialization Agreement for SYMJEPI and ZIMHI Products
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

New Data from Pivotal Phase 3 Study Investigating Lanadelumab as a Prophylactic Treatment for HAE to be Presented at 2018 AAAAI/WAO Joint Congress

New Data from Pivotal Phase 3 Study Investigating Lanadelumab as a Prophylactic Treatment for ...

author_avatar
NASDAQ Market News

Disease Transmission Models Can Help Forecast U.S. Election Outcome: Study

author_avatar
NASDAQ Market News

Diffusion Pharmaceuticals Receives Final FDA Protocol Guidance for Phase 3 Clinical Trial with TSC in Patients Newly Diagnosed with Inoperable Glioblastoma Multiforme

CHARLOTTESVILLE, Va., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) (“Diffusion” or ...

author_avatar
NASDAQ Market News